First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Related Keywords

Texas ,United States ,Houston ,Timothy Yap ,Therapeutics Discovery Division ,Translational Research ,University Of Texas Md Anderson Cancer Center ,Khalifa Institute For Personalized Cancer Therapy ,Clinical Development ,Investigational Cancer Therapeutics ,Phasei Program ,Neck Medical Oncology ,Cancer Center ,Khalifa Institute ,Personalized Cancer ,Project Optimus ,